XXXX in @entity1412 : a pilot project evaluating efficacy of treatment with @entity3131 .

@entity1 @entity137 @entity75 @entity5 @entity765 @entity3131 @entity8977 @entity74 @entity1412
OBJECTIVES: @entity3131 (Deskar, Marnac Inc., Dallas, TX), @entity3131 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity75 . METHODS: We enrolled 10 @entity1 and four @entity1 with extensive @entity1412 ( @entity1412 )-associated @entity8977 in a 2-yr open-label treatment trial with oral @entity3131 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity137 or drug intolerance was encountered. Seven @entity1 dropped out (three because of @entity74 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity1 experienced no change in @entity5 size or symptoms. CONCLUSIONS: @entity3131 is well tolerated by @entity1 with @entity1412 -associated @entity765 . Some @entity1 with @entity1412 treated with @entity3131 had regression of @entity5 , some had progression, and some had no response. @entity1 with rapidly growing @entity5 did not respond to @entity3131 . A placebo-controlled trial is needed to determine whether there is a subset of @entity1 for whom @entity3131 may result in partial shrinkage of @entity765 , because the natural history of @entity765 is not predictable or understood.
